In Latest NewsPosted April 15, 2021Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
In Latest NewsPosted March 4, 2021ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
In Latest NewsPosted December 1, 2020Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
